Application/Control Number: 10/627,372

Art Unit: 1614

## Request for Continued Examination (RCE)

Acknowledgement is made of applicants' filing of the instant application on March 07,
 as a Request for Continued Examination (RCE) under 37 CFR 1.1114.

## **EXAMINER'S AMENDMENT**

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Shantanu Basu on 03/23/07.

The application has been amended as follows:

In Claim 1, lines 2-4, delete [, or treating an inflammatory or metabolic disorder selected from the group consisting of metabolic syndrome, and inflammation caused by osteoarthritis].

In Claim 1, line 5, delete [, or an analog thereof].

In Claim 1, lines 5-7, delete [(a) at least partially activate peroxisome proliferation activated receptors (PPARs) and (b) at least partially inhibit, antagonize or block an activity of angiotensin II type 1 receptors] and replace with --increase the activity of a peroxisome proliferators activated receptor (PPAR) gamma--.

In Claim 2, lines 7-4, delete [, or treating the inflammatory or metabolic disorder].

In Claims 3, 9 and 10, lines 1-2, delete [, or an analog thereof,].

4-20-07